---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-088628"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T03:27:48.920040+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Theriva Biologics Q2 2023: $34.2M cash, VCN-01 trial on track, FDA orphan drug

## Summary
- Cash and equivalents $34.2M as of June 30, 2023, expected runway into Q4 2024.
- VIRAGE Phase 2b trial (VCN-01 + chemo) enrollment on track to complete Q1 2024; US sites dosing initiated.
- FDA granted orphan drug designation to VCN-01 for pancreatic cancer; previously for retinoblastoma.
- Ramon Alemany, Ph.D., appointed SVP of Discovery; continues as chair of Scientific Advisory Board.
- G&A expenses rose 80% to $2.7M; R&D expenses fell 10% to $3.1M vs Q2 2022.

## SEC filing metadata
- accession: 0001104659-23-088628
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465923088628/0001104659-23-088628-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465923088628/tm2322993d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-088628
- JSON: https://secwatch.observer/filing/0001104659-23-088628.json
- Plain text: https://secwatch.observer/filing/0001104659-23-088628.txt

## Key facts
- Earnings Releases
  Theriva Biologics, Inc. reported financial results for second quarter ended June 30, 2023.
  - Period: second quarter ended June 30, 2023
  - Result: reported results
  source text: On August 8, 2023, Theriva Biologics, Inc., a Nevada corporation (the “Registrant”) issued a press release that included financial information for its quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/894158/000110465923088628/0001104659-23-088628-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.